reports
Clearmind Medicine Announces Enrollment of First Patient in Phase I/II...
Clearmind Medicine Announces Enrollment of First Patient in Phase I/IIa Clinical Trial for Alcohol Use Disorder Treatment CMND-100 has the potential to provide an innovative and advanced treatment option for hundreds of millions of people around the world afflicted with Alcohol Use Disorder Vancouver, Canada, June 05, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today...
Metsera to Present New Research Highlighting the Breadth and Momentum ...
Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association® Four presentations on MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, including two clinical data presentations Additional preclinical presentations on other differentiated portfolio assets, including MET-233i, a monthly, ultra-long acting amylin analog NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR), a clinical-stage biopharmaceutical company accelerating...
Menang Corporation (M) Berhad: 1 director
A director at Menang Corporation (M) Berhad bought 2,400,000 shares at 0.750MYR and the significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last...
Gamuda Berhad: 2 directors
Two Directors at Gamuda Berhad sold 85,000 shares at between 4.700MYR and 4.730MYR. The significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last...
City Auto Corporation: 1 director
A director at City Auto Corporation bought 3,327,379 shares at 0.000VND and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
Fos S.p.A.: 1 director
A director at Fos S.p.A. bought 429,750 shares at 3.516EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
Saia Provides Second Quarter LTL Operating Data
Saia Provides Second Quarter LTL Operating Data JOHNS CREEK, Ga., June 05, 2025 (GLOBE NEWSWIRE) -- Saia, Inc. (Nasdaq: SAIA), a leading transportation provider offering national less-than-truckload (LTL), non-asset truckload, expedited and logistics services, is providing LTL shipment and tonnage data for the first two months of the second quarter. In April 2025, LTL shipments per workday declined 1.9%, LTL tonnage per workday increased 4.4% and LTL weight per shipment increased 6.5% to 1,418 pounds compared to 1,332 pounds in April 2024. In May 2025, LTL shipments per workday declined ...
Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for L...
Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia DUBLIN, June 05, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that LUMRYZTM has been granted Orphan Drug Designation (ODD) from the U.S. Food & Drug Administration (FDA) for the treatment of Idiopathic Hypersomnia (IH). Specifically, ODD was granted based on the plausible hypothesis that LUMRYZ ma...
Cellebrite to Acquire Corellium
Cellebrite to Acquire Corellium Combination Delivers Unmatched Innovation in Arm-based Vulnerability and Malware Research, Smart Device DevSecOps and Mobile Pen Testing TYSONS CORNER, Va. and PETAH TIKVA, Israel, June 05, 2025 (GLOBE NEWSWIRE) -- Cellebrite (NASDAQ: CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced its agreement to acquire Corellium, a leader in Arm-based virtualization software. This combination will set a new standard for digital investigations and the security of smart devices including iOS, Android,...
Bread Financial Announces Early Tender Results of Its Previously Annou...
Bread Financial Announces Early Tender Results of Its Previously Announced Cash Tender Offer COLUMBUS, Ohio, June 05, 2025 (GLOBE NEWSWIRE) -- Bread Financial Holdings, Inc. (NYSE: BFH) (“Bread Financial” or the “Company”) announced that as of 5:00 p.m., New York City time, on June 4, 2025 (the “Early Participation Date”), pursuant to and in accordance with its previously announced cash tender offer (the “Tender Offer”), approximately $536,786,000 in aggregate principal amount of the Company’s 9.750% Senior Notes due 2029 (the “Notes”) had been validly tendered and not validly withdrawn o...
Standard Uranium Announces Intent to Complete NI 43-101 Technical Repo...
Vancouver, British Columbia--(Newsfile Corp. - June 5, 2025) - Standard Uranium Ltd. (TSXV: STND) (OTCQB: STTDF) (FSE: 9SU0) ("Standard Uranium" or the "Company") is pleased to announce that it has contracted Axiom Exploration Group Ltd. ("Axiom") to complete a Technical Report (the "Report") in accordance with National Instrument 43-101 on the Corvo Uranium Project ("Corvo" or the "Project") located along the eastern margin of the Athabasca Basin, northern Saskatchewan, Canada. Corvo is currently under a three-year earn-in option agreement with Aventis Energy Inc. ("Aventis") (CSE: AVE).Axiom...
Colliers completes acquisition of Triovest
Colliers completes acquisition of Triovest TORONTO, June 05, 2025 (GLOBE NEWSWIRE) -- Global diversified professional services and investment management company, Colliers (NASDAQ, TSX: CIGI), announced today it has completed its previously announced acquisition of Triovest Inc. (“Triovest”), a leading Canadian commercial real estate services platform. The acquisition solidifies Colliers’ position as Canada’s largest commercial real estate services firm, employing more than 3,000 professionals, managing more than 95 million square feet of commercial real estate, and overseeing more than $1...
Bowman to Ring Nasdaq Opening Bell in Honor of 30th Anniversary
Bowman to Ring Nasdaq Opening Bell in Honor of 30th Anniversary Event Recognizes Bowman’s Journey from Local Firm to National Engineering Partner RESTON, Va., June 05, 2025 (GLOBE NEWSWIRE) -- Bowman Consulting Group Ltd. (NASDAQ: BWMN), a national engineering services and program management firm, will ring the Nasdaq Stock Market opening bell on June 9, 2025, commemorating its 30th anniversary. Founder and CEO, Gary Bowman, alongside members of the Company’s leadership team and employees, will participate in the ceremonial bell ringing at the Nasdaq MarketSite in Times Square. The eve...
Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumer...
Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress - DYNE-302 Demonstrated Functional Improvement in an FSHD Preclinical Model - WALTHAM, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced that it will be presenting new preclinical data demonstrating the potential of DYNE-302 to achieve functional improvement in facioscapulohumeral...
Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, ...
Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025 Emerging Biomarkers in the Clinical Development of Epilepsy Medicines and OV329 Program Highlights NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, will host an investor and media event on Thursday, June 12, 2025, on the topic of applying Biomarkers in Epilepsy, including their strategic use to demonstrate the pharmacodynamic activity of the Company’s OV329 clinical dev...
BioNTech SE: 1 director
A director at BioNTech SE sold 150,000 shares at 113.100USD and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
Seagate Technology Holdings Plc: 2 directors
A director at Seagate Technology Holdings Plc sold 20,000 shares at 109.472USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last ...
Microlink Solutions Berhad: 1 director
A director at Microlink Solutions Berhad sold 2,898,900 shares at 0.155MYR and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ...
Bintai Kinden Corp Bhd: 1 director
A director at Bintai Kinden Corp Bhd bought 2,113,400 shares at 0.075MYR and the significance rating of the trade was 36/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...
- Research Department
CAMBIO DE CARTERAS BANCO SABADELL SEMANA 28 MAYO AL 04 JUNIO 2025 (ANÁ...
Cartera Modelo Europa Sin cambios esta semana. Cartera High Yield Europa AB Inbev, Air Liquide, Airbus, ASML y AXA Sin cambios esta semana. Cartera Modelo España Sin cambios esta semana. Cartera 5 Valores España Cellnex, Ferrovial, IAG, Indra y Merlin Sin cambios esta semana. Cartera 5 valores High Yield España Acciona, Colonial, Iberdrola, Mapfre y Redeia Sin cambios esta semana. Cartera Pequeñas y Medianas España CAF, CIE Automotive, Enagás, Ence, Fluidra, Global Dominion, Indra, Mel...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.